Benzoic acid, 2-(acetyloxy)-, 3-[(nitrooxy)methyl]phenyl ester
| Title | Journal |
|---|---|
| Nitric oxide-releasing aspirin but not conventional aspirin improves healing of experimental colitis. | World journal of gastroenterology 20110928 |
| Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease. | European journal of pharmacology 20110601 |
| Nitric oxide (NO)-releasing aspirin exhibits a potent esophagoprotection in experimental model of acute reflux esophagitis. Role of nitric oxide and proinflammatory cytokines. | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20110201 |
| Comparison between 3-Nitrooxyphenyl acetylsalicylate (NO-ASA) and O2-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (NONO-ASA) as safe anti-inflammatory, analgesic, antipyretic, antioxidant prodrugs. | The Journal of pharmacology and experimental therapeutics 20101101 |
| Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent. | Diabetes care 20100601 |
| NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study. | The American journal of gastroenterology 20100501 |
| Effects of aspirin and NO-aspirin (NCX 4016) on platelet function and coagulation in human endotoxemia. | Platelets 20100101 |
| NO-donating aspirin and aspirin partially inhibit age-related atherosclerosis but not radiation-induced atherosclerosis in ApoE null mice. | PloS one 20100101 |
| Nitro-aspirin inhibits MCF-7 breast cancer cell growth: effects on COX-2 expression and Wnt/beta-catenin/TCF-4 signaling. | Biochemical pharmacology 20091115 |
| The differential cell signaling effects of two positional isomers of the anticancer NO-donating aspirin. | International journal of oncology 20091001 |
| Comparative effects of aspirin and NO-releasing aspirins on differentiation, maturation and function of human monocyte-derived dendritic cells in vitro. | International immunopharmacology 20090701 |
| New antiplatelet drugs: beyond aspirin and clopidogrel. | International journal of clinical practice 20090501 |
| Anti-inflammatory, antiproliferative, and cytoprotective activity of NO chimera nitrates of use in cancer chemoprevention. | Molecular pharmacology 20081101 |
| Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. | Journal of lipid research 20081001 |
| Fatty aspirin: a new perspective in the prevention of dementia of Alzheimer's type? | Current Alzheimer research 20081001 |
| NO-donating aspirin inhibits angiogenesis by suppressing VEGF expression in HT-29 human colon cancer mouse xenografts. | Carcinogenesis 20080901 |
| Nitric oxide (NO)-releasing aspirin and (NO) donors in protection of gastric mucosa against stress. | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20080801 |
| The nitric oxide-donating derivative of acetylsalicylic acid, NCX 4016, stimulates glucose transport and glucose transporters translocation in 3T3-L1 adipocytes. | American journal of physiology. Endocrinology and metabolism 20080701 |
| NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts. | Cell cycle (Georgetown, Tex.) 20080101 |
| NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols. | Journal of translational medicine 20080101 |
| Roles of platelet and endothelial cell COX-1 in hypercholesterolemia-induced microvascular dysfunction. | American journal of physiology. Heart and circulatory physiology 20071201 |
| Quinone formation as a chemoprevention strategy for hybrid drugs: balancing cytotoxicity and cytoprotection. | Chemical research in toxicology 20071201 |
| Nitroaspirin (NCX-4016), an NO donor, is antiangiogenic through induction of loss of redox-dependent viability and cytoskeletal reorganization in endothelial cells. | Antioxidants & redox signaling 20071101 |
| Nitric oxide-donating aspirin (NCX 4016) inhibits neointimal thickening in a pig model of saphenous vein-carotid artery interposition grafting: a comparison with aspirin and morpholinosydnonimine (SIN-1). | The Journal of thoracic and cardiovascular surgery 20071001 |
| Cardioprotective effects of nitric oxide-aspirin in myocardial ischemia-reperfused rats. | American journal of physiology. Heart and circulatory physiology 20070901 |
| Nitric oxide-releasing aspirin: will it say NO to atherothrombosis? | International journal of cardiology 20070531 |
| Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG. | International journal of cardiology 20070531 |
| Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin. | Journal of medicinal chemistry 20070517 |
| Effect of aspirin, paracetamol and their nitric oxide donating derivatives on exudate cytokine and PGE2 production in zymosan-induced air pouch inflammation in rats. | European journal of pharmacology 20070430 |
| Aspirin is a substrate for paraoxonase-like activity: implications in atherosclerosis. | Atherosclerosis 20070401 |
| Tissue factor and nitric oxide: a controversial relationship! | Journal of thrombosis and thrombolysis 20070401 |
| Susceptibility of the ocular lens to nitric oxide: implications in cataractogenesis. | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20070401 |
| [A novel class of anti-inflammatory and analgesic drugs--NO-donating NSAIDs]. | Yao xue xue bao = Acta pharmaceutica Sinica 20070401 |
| Prevention of transient endothelial dysfunction in acute exercise: a friendly fire? | Thrombosis and haemostasis 20070301 |
| Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication. | Thrombosis and haemostasis 20070301 |
| NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin. | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20061201 |
| Chronicles in drug discovery. | Drug news & perspectives 20061001 |
| Prevention of postischemic myocardial reperfusion injury by the combined treatment of NCX-4016 and Tempol. | Journal of cardiovascular pharmacology 20060901 |
| Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines. | Apoptosis : an international journal on programmed cell death 20060801 |
| Nitrogen oxide-releasing aspirin induces histone H2AX phosphorylation, ATM activation and apoptosis preferentially in S-phase cells: involvement of reactive oxygen species. | Cell cycle (Georgetown, Tex.) 20060801 |
| Mechanism of action of novel NO-releasing furoxan derivatives of aspirin in human platelets. | British journal of pharmacology 20060601 |
| Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. | Molecular cancer therapeutics 20060601 |
| NO-donating aspirin induces phase II enzymes in vitro and in vivo. | Carcinogenesis 20060401 |
| Nitric oxide and inflammation. | Inflammation & allergy drug targets 20060401 |
| NO-NSAIDs: from inflammatory mediators to clinical readouts. | Inflammation & allergy drug targets 20060401 |
| The effect of NCX4016 [2-acetoxy-benzoate 2-(2-nitroxymethyl)-phenyl ester] on the consequences of ischemia and reperfusion in the streptozotocin diabetic rat. | The Journal of pharmacology and experimental therapeutics 20060301 |
| Nitric oxide-donating aspirin inhibits colon cancer cell growth via mitogen-activated protein kinase activation. | The Journal of pharmacology and experimental therapeutics 20060101 |
| Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. | Cardiovascular drug reviews 20060101 |
| Ultracytochemical demonstration of soluble guanylate cyclase activation in rat aorta by NCX4016, a NO-releasing aspirin derivative. | Journal of submicroscopic cytology and pathology 20060101 |
| Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016). | The Journal of pharmacology and experimental therapeutics 20051201 |
| NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells. | Biochemical pharmacology 20051001 |
| Ultrastructural investigations on protective effects of NCX 4016 (nitroaspirin) on macrovascular endothelium in diabetic Wistar rats. | Journal of submicroscopic cytology and pathology 20050801 |
| Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intimal thickening in mice. | Thrombosis and haemostasis 20050301 |
| NSAIDs increase GM-CSF release by human synoviocytes: comparison with nitric oxide-donating derivatives. | European journal of pharmacology 20050131 |
| Nitric oxide-releasing aspirin derivative, NCX 4016, promotes reparative angiogenesis and prevents apoptosis and oxidative stress in a mouse model of peripheral ischemia. | Arteriosclerosis, thrombosis, and vascular biology 20041101 |
| Risk assessment of endogenous formation of carcinogenic N-nitroso compounds in response to intake of NO-aspirin. | Gastroenterology 20040901 |
| Nitroaspirins and morpholinosydnonimine but not aspirin inhibit the formation of superoxide and the expression of gp91phox induced by endotoxin and cytokines in pig pulmonary artery vascular smooth muscle cells and endothelial cells. | Circulation 20040831 |
| Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans. | Journal of the American College of Cardiology 20040804 |
| Theriac found? Nitric oxide-aspirin and the search for the universal cure. | Journal of the American College of Cardiology 20040804 |
| Nitric oxide regulates immune cell bioenergetic: a mechanism to understand immunomodulatory functions of nitric oxide-releasing anti-inflammatory drugs. | Journal of immunology (Baltimore, Md. : 1950) 20040715 |
| Cooperation between aspirin-triggered lipoxin and nitric oxide (NO) mediates antiadhesive properties of 2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) (NO-aspirin) on neutrophil-endothelial cell adherence. | The Journal of pharmacology and experimental therapeutics 20040601 |
| Nitric oxide release and distribution following oral and intraperitoneal administration of nitroaspirin (NCX 4016) in the rat. | Life sciences 20040514 |
| Chemiluminescence and LC-MS/MS analyses for the study of nitric oxide release and distribution following oral administration of nitroaspirin (NCX 4016) in healthy volunteers. | Journal of pharmaceutical and biomedical analysis 20040416 |
| Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors. | Canadian journal of gastroenterology = Journal canadien de gastroenterologie 20040401 |
| The influence on human osteoblasts in vitro of non-steroidal anti-inflammatory drugs which act on different cyclooxygenase enzymes. | The Journal of bone and joint surgery. British volume 20040401 |
| Antioxidant activity of nitro derivative of aspirin against ischemia-reperfusion in hamster cheek pouch microcirculation. | American journal of physiology. Gastrointestinal and liver physiology 20040301 |
| Polymorphism of NCX4016, an NO-releasing derivative of acetylsalicylic acid. | Journal of pharmaceutical sciences 20040301 |
| NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice. | Biochemical and biophysical research communications 20040116 |
| Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation. | American journal of physiology. Gastrointestinal and liver physiology 20040101 |
| Antiplatelet agents. | The hematology journal : the official journal of the European Haematology Association 20040101 |
| No-Aspirin (NCX 4016). | Gastroenterology 20031201 |
| Effect of nitric oxide-donating agents on human monocyte cyclooxygenase-2. | Biochemical and biophysical research communications 20031128 |
| Nitric oxide-donating aspirin inhibits beta-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin-TCF association. | Proceedings of the National Academy of Sciences of the United States of America 20031028 |
| Single oral dose study of two isosorbide-based aspirin prodrugs in the dog. | The Journal of pharmacy and pharmacology 20031001 |
| Nitric oxide-releasing aspirin inhibits vasoconstriction in perfused tail artery of normotensive and spontaneously hypertensive rats. | European journal of pharmacology 20030905 |
| Nitric oxide-releasing aspirin protects gastric mucosa against ethanol damage in rats with functional ablation of sensory nerves. | Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20030901 |
| NCX-4016 NicOx. | Current opinion in investigational drugs (London, England : 2000) 20030901 |
| Good news about gut-friendly aspirin. | Harvard health letter 20030801 |
| Implications of reactive oxygen species and cytokines in gastroprotection against stress-induced gastric damage by nitric oxide releasing aspirin. | International journal of colorectal disease 20030701 |
| NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines. | International journal of oncology 20030601 |
| Anti-arthritic agents--SMi conference: trapping cytokines. 28-29 April 2003, London, UK. | IDrugs : the investigational drugs journal 20030601 |
| Nitric oxide donating aspirins: novel drugs for the treatment of saphenous vein graft failure. | The Annals of thoracic surgery 20030501 |
| NO-aspirin: mechanism of action and gastrointestinal safety. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20030501 |
| NCX4016: a novel antithrombotic agent. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20030501 |
| NO-NSAIDs and cancer: promising novel agents. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20030501 |
| Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. | Gastroenterology 20030301 |
| Mandate to modify a medicinal mantra: maybe not yet? | Gastroenterology 20030301 |
| NCX-4016 (NO-aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo: role of nitric oxide. | Circulation 20021210 |
| NCX-4016, a nitric oxide-releasing aspirin, protects endothelial cells against apoptosis by modulating mitochondrial function. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20021001 |
| NCX 4016, a nitric oxide-releasing aspirin, modulates adrenergic vasoconstriction in the perfused rat tail artery. | British journal of pharmacology 20020901 |
| In vitro metabolism of a nitroderivative of acetylsalicylic acid (NCX4016) by rat liver: LC and LC-MS studies. | Journal of pharmaceutical and biomedical analysis 20020801 |
| Vascular protective actions of a nitric oxide aspirin analog in both in vitro and in vivo models of diabetes mellitus. | Free radical biology & medicine 20020601 |
| Potential cardioprotective actions of no-releasing aspirin. | Nature reviews. Drug discovery 20020501 |
| NCX4016 (NO-aspirin) reduces infarct size and suppresses arrhythmias following myocardial ischaemia/reperfusion in pigs. | British journal of pharmacology 20020401 |
| Nitrosylhemoglobin, an unequivocal index of nitric oxide release from nitroaspirin: in vitro and in vivo studies in the rat by ESR spectroscopy. | Journal of pharmaceutical and biomedical analysis 20011101 |
| NCX4016 (NO-Aspirin) has multiple inhibitory effects in LPS-stimulated human monocytes. | British journal of pharmacology 20011001 |
| Vasorelaxant effect of nitric oxide releasing steroidal and nonsteroidal anti-inflammatory drugs. | British journal of pharmacology 20010801 |
| Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats. | British journal of pharmacology 20010801 |
| Low gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in rats with cirrhosis and arthritis. | Digestive diseases and sciences 20010801 |
| Effect of cyclooxygenase-2 inhibitor (celecoxib) on the infarcted heart in situ. | Pharmacology 20010701 |
| NO-releasing NSAIDs are caspase inhibitors. | Trends in immunology 20010501 |
| Nitro-aspirin (NCX4016) reduces brain damage induced by focal cerebral ischemia in the rat. | Neuroscience letters 20010420 |
| The nitroderivative of aspirin, NCX 4016, reduces infarct size caused by myocardial ischemia-reperfusion in the anesthetized rat. | The Journal of pharmacology and experimental therapeutics 20010401 |
| NCX4016 (NO-aspirin) inhibits thromboxane biosynthesis and tissue factor expression and activity in human monocytes. | Medical science monitor : international medical journal of experimental and clinical research 20010101 |